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BackgrounaYAims: Oxidative stress could play a role 
in the pathogenesis of hepatitis C virus infection. We 
investigated the oxidant/antioxidant status in periph- 
eral blood mononuclear cells from patients with 
chronic hepatitis C and controls. 
Methods/Results: Lipid peroxidation products and su- 
peroxide dismutase activity in peripheral blood mono- 
nuclear cells were higher in chronic hepatitis C pa- 
tients than in healthy subjects while glutathione S- 
transferase activity was reduced in patients as com- 
pared to controls. Catalase, glutathione peroxidase 
and glutathione reductase were similar in chronic 
hepatitis C and normal individuals. No statistically 
significant differences were found between patients 
and controls with regard to glutathione levels in pe- 
ripheral blood mononuclear cells, but 35% of patients 
LUTATHIONE (GSH), the most abundant non-en- G zymatic antioxidant present in cells, plays an im- 
portant role in the defense against oxidative-stress-in- 
duced cell injury (1). Cells of the immune system are 
exposed during inflammatory processes to large 
amounts of reactive oxygen intermediates, and thus 
need an efficient glutathione system to neutralize free 
radicals, which could otherwise disturb immune func- 
tions (2,3). In cells glutathione is present mainly in its 
reduced form. Reduced GSH can be converted to oxid- 
ized glutathione (GSSG), which is revertible to the re- 
duced form with the enzyme glutathione reductase 
(GR). Glutathione reductase is a widespread flavopro- 
tein that accounts for the very high GSHlGSSG ratios 
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with chronic hepatitis C showed values of glutathione 
and oxidized glutathione which were below and above, 
respectively, the limits of normal controls. Finally, the 
glutathione synthetic capacity of the cytosol of pe- 
ripheral blood mononuclear cells was significantly 
higher in patients than in controls, indicating in- 
creased glutathione turnover in lymphocytes from pa- 
tients with chronic hepatitis C. 
Conclusions: Oxidative stress is observed in periph- 
eral blood mononuclear cells from chronic hepatitis C 
patients. This process might alter lymphocyte function 
and facilitate the chronic@ of the infection. 
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found in cells (1,4). GSH can be synthesized de now 
from precursor aminoacids by two ATP-dependent 
cytosolic reactions catalyzed by y-glutamyl cysteine 
synthetase (pGCS) and glutathione synthetase (1). 
Cells are also equipped with enzymatic antioxidant 
mechanisms that play an important role in the elimin- 
ation of free radicals. Superoxide dismutase (SOD), 
catalase and glutathione peroxidase (GPX) are en- 
zymes involved in the clearance of superoxide and hy- 
drogen peroxide (H202). SOD catalyzes the dismuta- 
tion of superoxide into H202, which has to be elimin- 
ated by GPX and/or catalase (5). Another important 
antioxidant enzymatic system is represented by isoen- 
zymes of glutathione S-transferase (GST). These en- 
zymes catalyze the conjugation of GSH with toxic 
compounds, to generate glutathione S-conjugates 
which are excreted outside the cell (6). GSTs are also 
known to be involved 1 the protection of cellular 
membranes by neutralizing lipid hydroperoxides using 
reduced GSH as a cofactor (4,7). 
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Antioxidant status and HCV infection 
Hepatitis C virus (HCV) is the main causative agent 
of chronic viral hepatitis. Chronic hepatitis C (CH-C) 
can progress to cirrhosis and eventually to hepatocellu- 
lar carcinoma over a period of 20-30 years. The mech- 
anisms by which HCV causes cell damage are not well 
understood. Different mechanisms including immuno- 
logical liver damage, direct cytotoxicity mediated by 
different viral products and induction of oxidative 
stress have been suggested as playing a pathogenic role 
in this infection (8). Oxidative liver injury has been 
proposed in chronic hepatitis C, as increased levels of 
lipid peroxidation products (such as malondialdehyde, 
MDA) are found in both serum (9) and liver (10-12) 
from CH-C patients compared to healthy controls. 
Also, administration of N-acetyl-cysteine in addition 
to interferon (IFN) facilitates the biochemical response 
to this antiviral drug in IFN-resistant CH-C patients 
(13). 
Hepatitis C virus infects hepatocytes as well as 
lymphoid cells (14,15). In previous work (16) we have 
found increased mRNA levels of manganese-depend- 
ent SOD (Mn-SOD) in peripheral blood mononuclear 
cells (PBMC) from patients with chronic HCV infec- 
tion, suggesting that oxidative stress might be present 
in peripheral lymphocytes in this condition. Since the 
therapeutic response to IFN depends critically on the 
ability of this compound to stimulate an efficient anti- 
viral immune response (17,18), and oxidative stress is 
known to impair the effector functions of lymphocytes 
(3), we decided to investigate further the presence of 
oxidative stress in PBMC from HCV-infected individ- 
uals. We therefore determined MDA, GSH and GSSG 
levels, GSH synthetic capability, mRNA expression for 
y-GCS, and the activities of SOD, catalase, GPX, GR 
and GST in peripheral blood mononuclear cells from 
patients with chronic hepatitis C and healthy controls. 
Materials and Methods 
Patients 
Because of the excessive amount of blood needed for all the labora- 
tory procedures included in the present study, two different cohorts 
of patients were analyzed. Written consent was obtained in all cases. 
The first cohort comprised 20 patients with CH-C (11 males and 9 
females, age range from 31 to 79 years; 3 cases showed liver cirrhosis 
and 18 were infected with genotype lb). All the patients from this 
cohort were non-responders to IFN treatment (19). In this cohort we 
measured the antioxidant enzyme activities and MDA levels. 
In the second cohort we determined oxidized and reduced GSH 
levels, GSH synthetic capability, and the expression of y-GCS. This 
group included 29 patients with chronic hepatitis C (21 males and 8 
females, age range from 23 to 67 years; 2 patients had liver cirrhosis 
and 20 cases were infected with genotype lb). In this cohort 19 pa- 
tients were non-responders to IFN treatment, 5 patients had never 
received IFN treatment, and the rest showed partial biochemical or 
virological responses to IFN. 
Both cohorts were comparable with regard to disease activity and 
had similar levels of albumin, bilirubin, yGT, AST and ALT (3.920.1 
g/dl, 0.81?0.05 mg/dl, 34.1?5.0 U/l, 51.9214.1 U/l and 82.32155 
U/l, respectively for cohort 1 and 4.2kO.1, 0.69?&07, 35.825.0, 
45.224.1 and 81.6k8.3 for cohort 2; not significant (ns) for all vari- 
ables when comparing the two cohorts). Biochemical parameters were 
also similar in the subsets of patients within each cohort who were 
subjected to different analytical determinations (data not shown). 
A group of 24 healthy volunteers (10 males and 14 females, ages 
26 to 72) served as controls for the first cohort, and 35 healthy volun- 
teers (17 males and 18 females, from 20 to 67 years of age) served as 
controls for the second cohort. Both groups of controls were compar- 
able in age and sex. 
In all cases the diagnosis of chronic hepatitis C was based on raised 
serum transaminases for at least 6 months, positivity for anti-HCV 
antibodies (ELISA Second Generation, Ortho Diagnostic System, 
USA), and the presence of HCV-RNA by reverse transcription-PCR 
in serum (19). HCV detection, quantitation and genotyping were per- 
formed as previously described (16,19). Histological evidence of 
chronic hepatitis was assessed in all cases. None of the patients had 
received interferon treatment for at least 3 months previous to the 
study. 
Isolation of PBMC and preparation of cytosol 
Blood was collected in heparinized tubes from the patients after an 
overnight fast, and PBMC were isolated as previously described (20). 
Less than 30 min elapsed between the blood extraction and PBMC 
isolation. All steps from this point were carried out at 4°C. For MDA 
and antioxidant enzyme activities, cytosolic extracts from 20X106 
PBMC were prepared essentially as described (21). Cells were allowed 
to swell up for 20 min in cold buffer A (10 mM HEPES pH 7.9, 10 
mM KCl, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM PMSF) and 
disrupted by vortexing after Nonidet-P40 addition. Nuclei were pel- 
leted by centrifugation (30 s at 15 000 g, 4°C) and cytosolic extract 
was cleared by centrifugation (5 min at 15 000 g, 4°C). 
In the experiments involving GSH determinations, isolated PBMC 
were disrupted by ultrasonation (Sonifier 250, Branson, USA) in two 
10-s sessions. The cytosolic fraction was purified by ultracentrifuga- 
tion at 100 000 g for 1 h at 4°C. One aliquot of the supernatant was 
used for total glutathione determinations and for GSH/GSSG quanti- 
fication. Another aliquot of cytosol was used to measure GSH syn- 
thetic capability. Total protein concentration in cytosols was deter- 
mined using the Bio-Rad protein assay (Bio-Rad Laboratories, USA) 
using BSA standards. All samples were stored at -80°C. 
Lipid peroxidation 
MDA in PBMC was used as an index of lipid peroxidation. Determi- 
nations were performed using the calorimetric assay for lipid peroxi- 
dation Bioxytech@ LPO-586 (Oxis International, France), which after 
reacting with MDA, generates a stable chromophore that was meas- 
ured at 586 nm in a Hitachi U2000 Spectra (Boehringer Mannheim, 
Germany). 
Activity of antioxidant enzymes 
SOD, catalase, GR, GPX, and GST activities in cytosolic extract from 
PBMC were spectrophotometrically measured in a Cobas Mira (Ro- 
the Diagnostica, Switzerland) as previously described (22). Briefly, 
SOD (E.C. 1.15.1.1) activity was determined at 37°C with the commer- 
cially available kit “Ransod” (Randox, UK), adapted to the Cobas 
Mira. Catalase (E.C. 1.11.1.6) activity was determined at 25°C accord- 
ing to the method of Goth (23). GR (E.C.l.6.4.2) activity was also 
measured with the “Glutathione Reductase” package (Randox, UK) 
also adapted to a Cobas Mira autoanalyzer. GPX (E.Cl .11.1.9) was 
determined at 37°C with the commercial kit “Ransel” (Randox, UK), 
using the Cobas Mira autoanalyzer. GST (E.C.2.5.1.18) was colorim- 
etrically determined in the Cobas Mira at 340 nm (6). 
Total glutathione and reduced and oxidized fractions 
Total glutathione was measured according to Tietze (24). The method 
is based on the reaction with dithionitrobenzoic acid (DTNB) in the 
presence of glutathione-reductase and NADPH. Absorbances at 420 
nm from each sample were interpolated in a GSH standard curve, 
and glutathione concentrations were expressed as nmol/mg protein. 
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Fig. 1. Malondialdehyde (MDA) levels in peripheral blood 
mononuclear cells from chronic hepatitis C (CH-C) pa- 
tients and healthy controls (C). 
PBMC cytosolic fraction from HCV-infected patients and healthy 
controls was used to quantify, by high pressure liquid chromatogra- 
phy (HPLC), GSH and GSSG following a method previously de- 
scribed (25) with slight modifications (26). Briefly, 300 ~1 of the cyto- 
solic fraction obtained as indicated above were immediately derivatiz- 
ed using 1-fluoro-2,4-dinitrobenzene. Samples were then chromato- 
graphed on a 3-aminopropyl-Spherisorb, 20 cmX4.6 mm, 5 pm 
HPLC column, equilibrated in 80% methanol. Elution was performed 
with 0.5 M sodium acetate in 64% methanol and followed at 365 nm. 
GSH synthetic rate 
PBMC cytosols from HCV-infected patients and controls were dial- 
yzed overnight at 4°C to deplete cytosolic GSH content in order to 
minimize feedback inhibition of y-GCS by GSH. The capacity to syn- 
thesize glutathione was determined using monochlorobimane (mBC1) 
as described by Fernandez-Checa & Kaplowitz (27). Monochlorobi- 
mane binds GSH specifically in a reaction catalyzed by the enzyme 
glutathione S-transferase. GSH-mBC1 adducts were measured by a 
fluorimetric technique, in a Perkin Elmer Luminiscence Spectro- 
photometer LS-SOB (Perkin Elmer, USA), with excitation at 392 nm 
and emission at 477 nm, with a slit width of 3.0 nm for both exci- 
tation and emission monochromators. The GSH synthetic rate is de- 
fined as the net increase in the fluorescence signal (slope per minute) 
obtained by subtracting the fluorescence signal per minute in the pres- 
ence of buthionine-sulfoximine (BSO) from that in the absence of 
BSO. This compound irreversibly inhibits y-GCS, the limiting step in 
de nova GSH synthesis. The difference in fluorescence per minute was 
converted to concentration of GSH using the GSH calibration curve. 
All samples were measured in triplicate. GSH synthetic rate was ex- 
pressed as nmol of GSH./min/mg of protein. 
RNA extraction and RT-PCR determinations 
y-GCS mRNA was determined by semi-quantitative RT-PCR in a 
Perkin-Elmer Gene Amp PCR System 2400 (Perkin Elmer, USA). 
Total RNA was obtained from PBMC lysed in the UltraspecTM RNA 
isolation system (Biotecx Laboratories, USA), and reverse tran- 
scribed as previously described (20). 0.3 pg of cDNA was used for 
PCR amplification with specific primers which amplify a fragment 
426 bp long from human hepatic y-GCS gene (28), upstream primer 
(5’-3’) d(AGA TGA TAG AAC TCG GGA GG) and downstream 
(5’-3’) d(GCC TAT GTG GTG TTT GTG GGT). y-GCS cDNA 
fragments were amplified 26 cycles, a protocol that avoided inter- 
ference of the plateau effect. As internal control for each sample, a 
fragment of /?-actin cDNA was amplified (20). We have reported that 
b-actin mRNA expression does not change in liver or PBMC in CH- 
C (20). PCR products were electrophoresed in 2% agarose gel stained 
with ethidium bromide. The bands obtained were analyzed with com- 
mercial software (Molecular Analyst/PC, Bio-Rad, USA). y-GCS 
mRNA values were normalized to those of /I-actin mRNA and results 
were expressed as y-GCS to p-actin ratio. Restriction enzyme diges- 
tion was performed to assess the specificity of the PCR reaction for 
the y-GCS. 
Statistical analysis 
Data are presented as mea&standard error of the mean. Normality 
was assessed with the Shapiro-Wilks test. For normal distributions 
parametric tests were performed (Student t-test) and non-parametric 
analyses were performed in all other cases (Mann-Whitney, Kruskall- 
Wallis). Outliers in normal populations were filtered with at least a 
0.01 confidence interval. Associations between variables were studied 
with Pearson’s correlation coefficient. All p-values were 2-tailed and 
were considered statistically significant when the associated prob- 
ability was less than 0.05. Statistical analysis was performed with the 
SSPS for Windows (6.1.3 version). 
Results 
In CH-C patients (n= 13) MDA levels in PBMC were 
significantly increased as compared to healthy subjects 
(n=12) (3.9520.17 vs. 3.2520.14 pmol/g protein, 
p<O.O05, Fig. I). Table 1 shows the activities of anti- 
oxidant enzymes in PBMC from CH-C patients and 
normal controls. A significant rise in Mn-SOD activity 
and a significant reduction in the activity of GST were 
found in HCV-infected individuals as compared with 
control subjects. The activities of catalase, GPX and 
GR were similar in patients and controls. 
TABLE 1 
Antioxidant enzyme activities in cytoplasmic extracts from PBMC in healthy controls and chronic hepatitis C (CH-C) patients 
Healthy controls CH-C p-value 
Mn-SOD (U/g prot.) 221?4* (n=lO) 23722 (n=lO) co.005 
Catalase (KU/g prot.) 70.328.3 (n=l7) 78.6rt9.7 (n=l9) ns 
GPX (U/g prot.) 509.3226.3 (n=l6) 431.2k35.5 (n=l8) ns 
GR (U/g prot.) 143.121.2 (n=lO) 146.3k2.6 (n=l2) ns 
GST (U/g prot.) 281.823.3 (n=9) 264.225.9 (n=lO) <0.05 
* Mean+SEM. 
810 
Antioxidant status and HCV infection 
Fig. 2. (A) Reduced gluta- 
thione (GSH) and (B) oxid- 
ized glutathione (GSSG) 
levels in peripheral blood 
mononuclear cells from 
chronic hepatitis C (CH-C) 
patients and healthy controls 
(C). 
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Total glutathione in PBMC cytosols were compar- 
able in HCV-infected patients (n=29) and in normal 
individuals (n=35) (46.522.2 vs. 51.9-t 1.9 nrnol/mg 
protein, ns). The values of GSH and GSSG in PBMC, 
as estimated by HPLC, were also not significantly dif- 
ferent in patients (38.8+2 and 2.420.1 nmol/mg pro- 
tein, n=14) and healthy controls (42.421.3 and 
0.320.2 nmol/mg protein, n=lO) (Fig. 2). Despite the 
absence of statistical significance, there was a tendency 
to lower GSH values and higher GSSG in HCV infec- 
tion than in normal subjects, with about one third of 
patients exhibiting GSSG concentrations above the 
upper limit of normal values and GSH values below 
the lower limit of normal controls (Fig. 2). Interest- 
ingly, those patients who showed elevated GSSG values 
had, as compared to healthy controls, decreased GSH 
levels (42.4% 1.3 vs. 34.Ok3.6 nmol/mg protein, 
pcO.05). 
GSH synthesis by purified PBMC cytosol was 
studied in 27 healthy controls and 21 patients with CH- 
C. The rate of GSH production in samples from nor- 
mal individuals was 1.7420.34 nmol/mg protein/min, 
the rate of synthesis was not affected by age or sex of 
the subject (data not shown). In PBMC from healthy 
controls, the GSH synthesis rate significantly corre- 
lated with the total GSH content (r=0.51, n=27, 
p<O.Ol), and reduced GSH levels (r=0.98, n=5, 
p<O.O05). HCV-infected patients showed a significant 
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Fig. 3. Capability of glutathione (GSH) synthesis in pe- 
ripheral blood mononuclear cells from chronic hepatitis C 
(CH-C) patients and healthy controls (C). 
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increase in GSH synthesis rate in PBMC as compared 
to controls (2.4720.27 vs. 1.7420.34 nmol/mg protein/ 
min, ~~0.01, Fig. 3). Interestingly, patients who did 
not respond to IFN treatment had an even higher 
GSH-synthesis rate (2.7OkO.44 vs. 1.7420.34 nmol/mg 
protein/min, p~O.001, non-responders and controls, 
respectively), and in these cases the levels of y-GCS 
mRNA in PBMC were significantly higher than in con- 
trols (0.6220.03 vs. 0.53+0.02, p<O.OS). In patients 
with CH-C, no significant correlation was found be- 
tween GSH values and GSH synthesis rate. 
We found no correlation between the oxidative stress 
parameters tudied in PBMC and the HCV-RNA titer 
or the aminotransferases levels in serum. 
Discussion 
Our results show that PBMC from patients with CH- 
C have increased MDA concentrations and enhanced 
SOD activity. MDA is a reflection of lipid peroxidation 
and SOD is an important antioxidant defense enzyme 
that converts superoxide into hydrogen peroxide. In- 
creased SOD activity appears to be an adaptive re- 
sponse to increased generation of superoxide ions (29). 
Thus, our findings support the existence of oxidative 
stress in PBMC from patients with chronic HCV infec- 
tion and are in agreement with previous data from our 
group showing increased Mn-SOD mRNA values in 
PBMC from these patients (16). 
One of the factors, which may be responsible for 
oxidative stress in HCV infection, is the increased pro- 
duction of proinflammatory cytokines reported to oc- 
cur in this condition. Raised serum tumor necrosis fac- 
tor alpha (TNF-alpha) and increased TNF-alpha 
mRNA values in PBMC have been found in subjects 
with chronic HCV infection (20). TNF-alpha causes 
increased production of superoxide in mitochondria 
(30,31) and induces, both directly and indirectly, Mn- 
SOD upregulation (32,33). In addition to inflamma- 
tory mediators, oxidative stress can also be produced 
as a direct consequence of viral replication. In this re- 
spect it should be considered that HCV infects not only 
hepatocytes but also lymphocytes and monocytes 
(14,16,34), and thus it can cause direct cytopathic ef- 
fects in the liver as well as in lymphoid cells. 
SOD dismutates superoxide to hydrogen peroxide 
and this compound is catabolized by catalase and 
GPX. The latter two enzymes and also GR, which re- 
duces GSSG to GSH, show normal values in PBMC 
from CH-C patients. However, although these enzy- 
matic activities are not significantly decreased, the 
adaptive antioxidant response of SOD is not concomi- 
tantly accompanied by GPX and/or catalase upregula- 
tion. Several studies have suggested that, to avoid lipid 
peroxidation, increased SOD activity should be ac- 
companied by a rise in GPX activity (SODIGPX ratio) 
(3540). In consequence, an unbalanced antioxidant re- 
sponse could contribute to lipid peroxidation in 
chronic hepatitis C. Another factor that might partici- 
pate in causing lipid peroxidation is the decrease in glu- 
tathione S-transferase observed in cases with HCV in- 
fection. GSTs are a family of antioxidant and detoxi- 
fication enzymes, which account for the non-selenium- 
containing glutathione peroxidase activity (4). Thus, 
reduced GST activity may diminish the efficacy of an 
enzymatic function that is critical in the protection of 
cell membranes, neutralizing lipid peroxides using 
GSH as cofactor (7,41). The mechanisms responsible 
for reduced GST activity in HCV infection were not 
investigated in the present study. However, it has been 
reported that some viral proteins such as SV40 T anti- 
gen and adenovirus El A have the ability to down-regu- 
late the endogenous expression of glutathione S-trans- 
ferase, an effect which has been thought to contribute 
to their carcinogenic potential (42). On the other hand, 
decreased GST activity is also found in the liver from 
HBV (hepatitis B virus)-infected patients, and the ac- 
tivity is further decreased uring hepatocellular tumor- 
ogenesis, suggesting that cellular protection within the 
human liver is compromised in HBV-infected individ- 
uals (43). HCV also causes carcinogenesis, not only in 
the liver (44) but also in the lymphoid system (45). It 
is thus possible that reduced GST activity might play 
a role in various cytopathic effects exerted by HCV 
Glutathione plays a pivotal role in the defense 
against oxidative insult, as a cofactor of glutathione 
peroxidases (selenium dependent and independent) 
participates in the elimination of hydrogen peroxide 
and lipid hydroperoxides (4,5,7). Our findings of high 
MDA values and high SOD activity in CH-C seem to 
indicate increased consumption of GSH in this con- 
dition. This increased consumption appears to be com- 
pensated by an increased GSH production, to maintain 
normal or quasi-normal GSH levels. In fact, in the 
present study we observed enhanced GSH synthetic ca- 
pacity in patients with CH-C, especially in those who 
did not respond to IFN therapy. Interestingly, in these 
cases the mRNA levels of y-GCS, a critical enzyme in 
the GSH synthesis, were significantly increased as com- 
pared to healthy controls. It should be noted, however, 
that despite increased GSH synthetic capacity, about 
one third of the patients showed levels of GSH below 
the lower limit of control values and GSSG concen- 
tration above the upper limit of controls. 
To our knowledge the present report is the first to 
analyze GSH biosynthetic capacity in human cells. 
Interestingly, our results are similar to those of Fernan- 
812 
dez-Checa & Kaplowitz in isolated rat hepatocytes 
(27). In our study, PBMC cytosolic fraction was con- 
centrated and glutathione-depleted to avoid feedback 
inhibition by the final reaction product. These experi- 
mental conditions allowed us to determine maximum 
GSH synthesis. Our results in healthy subjects showed 
that GSH biosynthetic capacity correlated significantly 
with total and reduced GSH content. However, this 
correlation is lost in patients, probably because in ad- 
dition to biosynthetic capacity, other factors, such as 
increased GSH consumption, are influencing intra- 
cellular glutathione stores. 
Taken together, our data indicate the presence of 
oxidative stress and an adaptive antioxidant response 
in PBMC from CH-C patients. The defensive antioxi- 
dant response includes high SOD activity and in- 
creased GSH biosynthetic activity. Despite activation 
of GSH biosynthesis, GSH remain within or below 
normal values, indicating increased GSH turnover. 
Oxidative stress may affect the efficiency of the effector 
mechanisms of the immune response (39), and it has 
also been shown to make cells more susceptible to 
apoptosis (46). It is possible, therefore, that oxidative 
stress in lymphoid cells may impair the antiviral im- 
mune response, thus facilitating chronicity of HCV in- 
fection. 
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